Invention:
This invention is a method of therapeutic intervention for primary and metastatic brain cancer, and other relevant nervous system derivates, via the deliverances of deuterated heavy water isotopologue. This novel treatment method offers promise for specificity improvements as it uses water to deliver its therapy, allowing for increased efficiency in crossing the blood-brain barrier after treatment.
Background:
According to the National Brain Tumor Society, an estimated 1 million Americans are living with a primary brain tumor. Brain cancer is estimated to be the 10th leading cause of cancer death in 2023 for both males and females in all age groups, with Glioblastoma being the most commonly occurring primary malignant brain tumor, accounting for 14.2% of all tumors. Most therapies for brain cancer effectively lack the ability to pass through the blood-brain barrier, decreasing overall specificity and success. This novel technology utilizes heavy water isotopologue to achieve effective central nervous system (CNS) deuteration for treatment of brain cancer and other CNS-related issues.
Applications:
- Glioblastoma and brain cancer therapeutics
- CNS therapeutics
- Deuterated drug delivery
Advantages:
- Increased ability to pass through blood-brain barrier
- Utilizes novel deuteration techniques
- Proven therapeutic efficacy in targeting and eliminating cancer cells
